Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells

Engineered mesenchymal stromal cells (MSC) have been used in many preclinical studies of gene directed enzyme/prodrug therapy. We aimed to compare the efficacy of two most frequently used systems, as well as evaluate the extent of a bystander effect mediated by therapeutic MSC towards cell lines derived from different tumours.

[1]  Brian J. Wilson,et al.  ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. , 2011, Cancer research.

[2]  V. Altanerová,et al.  Stem cell based cancer gene therapy. , 2011, Molecular pharmaceutics.

[3]  E. Maccaroni,et al.  5-Fluorouracil pharmacogenomics: still rocking after all these years? , 2011, Pharmacogenomics.

[4]  D. Rosskopf,et al.  Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil , 2011, Drug Metabolism and Disposition.

[5]  P. Schiller,et al.  Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. , 2010, Biomaterials.

[6]  Mustapha Kandouz,et al.  Gap junctions and connexins as therapeutic targets in cancer , 2010, Expert opinion on therapeutic targets.

[7]  S. Scheding,et al.  Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  M. Matúšková,et al.  HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. , 2010, Cancer letters.

[9]  C. Kang,et al.  The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells , 2010, Cancer Gene Therapy.

[10]  Toshiaki Tanaka,et al.  Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: a partial contribution of gap junctions. , 2009, Cancer letters.

[11]  C. Choi,et al.  Detection of drug transporter expression using a 25-multiplex RT-PCR assay , 2009, Biotechnology Letters.

[12]  F. Gago,et al.  The dual role of thymidine phosphorylase in cancer development and chemotherapy , 2009, Medicinal research reviews.

[13]  T. Nguyen,et al.  Regulation of gap junctional intercellular communication by TCDD in HMEC and MCF-7 breast cancer cells. , 2009, Toxicology and applied pharmacology.

[14]  M. Matúšková,et al.  Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice , 2008, The journal of gene medicine.

[15]  M. Danks,et al.  Stem and progenitor cell-mediated tumor selective gene therapy , 2008, Gene Therapy.

[16]  M. Matúšková,et al.  Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. , 2007, Cancer research.

[17]  M. Renner,et al.  Suicide genes for cancer therapy. , 2007, Molecular aspects of medicine.

[18]  R. Ueda,et al.  MRP8/ABCC11 directly confers resistance to 5-fluorouracil , 2007, Molecular Cancer Therapeutics.

[19]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[20]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[21]  D. Shewach,et al.  GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity , 2005, Gene Therapy.

[22]  P. Johnston,et al.  The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites , 2005, Molecular Cancer Therapeutics.

[23]  P. Mantyh,et al.  Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. , 2003, Cancer research.

[24]  Zhe-Sheng Chen,et al.  MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2′,3′-Dideoxycytidine and 9′-(2′-Phosphonylmethoxyethyl)adenine* , 2003, Journal of Biological Chemistry.

[25]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[26]  J. Schuetz,et al.  Expression of MRP4 Confers Resistance to Ganciclovir and Compromises Bystander Cell Killing* , 2002, The Journal of Biological Chemistry.

[27]  G. Batist,et al.  The Role of Connexin-Mediated Cell–Cell Communication in Breast Cancer Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[28]  V. Mautner,et al.  In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase , 2001, Gene Therapy.

[29]  H. Hamada,et al.  Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. , 2000, European journal of cancer.

[30]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[31]  P. Leroy,et al.  In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. , 2000, Cancer research.

[32]  H. Hamada,et al.  Circumvention of 5‐Fluorouracil Resistance in Human Stomach Cancer Cells by Uracil Phosphoribosyltransferase Gene Transduction , 1999, Japanese journal of cancer research : Gann.

[33]  S. H. Chen,et al.  Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. , 1998, Cancer research.

[34]  R. Ramesh,et al.  Immune system in suicide-gene therapy , 1997, The Lancet.

[35]  D. Klatzmann,et al.  Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". , 1996, Cancer gene therapy.

[36]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[37]  D. Faulds,et al.  Ganciclovir , 1990, Drugs.

[38]  R. McIvor,et al.  Facilitated transport of uracil and 5‐fluorouracil, and permeation of orotic acid into cultured mammalian cells , 1980, Journal of cellular physiology.

[39]  C. Jorgensen,et al.  Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. , 2008, Current stem cell research & therapy.

[40]  H. Wolburg,et al.  Structure--function relationships in gap junctions. , 1995, International review of cytology.

[41]  G. Milano,et al.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. , 1994, European journal of cancer.

[42]  J. Trosko,et al.  Endogenous and exogenous modulation of gap junctional intercellular communication: toxicological and pharmacological implications. , 1993, Life sciences.